c-kit Expression and mutations in peripheral T cell lymphomas, except for extra-nodal NK/T cell lymphomas

Area of Science:

• Hematology
• Oncology
• Molecular Biology

Background:

• Peripheral T-cell lymphomas (PTCLs) are aggressive non-Hodgkin lymphomas with limited targeted therapy options.
• The c-kit receptor tyrosine kinase is a potential therapeutic target in various cancers.
• Evaluating c-kit expression and mutations in PTCLs is crucial for identifying new treatment strategies.

Purpose of the Study:

• To determine the expression levels and mutation status of c-kit in PTCLs.
• To evaluate the potential of c-kit as a therapeutic target for PTCL treatment with imatinib mesylate.

Main Methods:

• Immunohistochemistry was used to assess c-kit expression in 52 PTCL patients.
• Polymerase chain reaction-single-stranded conformational polymorphism and DNA sequencing were employed to analyze c-kit mutations in paraffin-embedded specimens.

Main Results:

• Weak c-kit expression was observed in 30.8% of PTCL patients.
• Mutations in c-kit exons 11 or 13 were identified in only 5.8% of patients.
• Specific mutations included codon 558 (Lys-Stop), 571 (Leu-Ile) in exon 11, and 634 (Arg-Arg) in exon 13.

Conclusions:

• The low frequency of c-kit mutations in PTCLs suggests it is not a suitable target for imatinib mesylate therapy.
• Further research may be needed to identify alternative targeted therapies for PTCLs.